Skip to content

Psychedelics and Dying Care: A Historical Look at the Relationship between Psychedelics and Palliative Care.

Erika Dyck

Journal of psychoactive drugs January 1, 2019 Peer reviewed DOI: 10.1080/02791072.2019.1581308 via PubMed

Summary

Psychedelics were historically explored for their potential to ease anxiety associated with dying, particularly in the context of palliative care. Initially, these substances were investigated in the 1950s before being criminalized, which led to a loss of early discussions on their therapeutic use. The article reflects on how understanding past applications of psychedelics can inform contemporary conversations about their role in palliative care.

Study at a glance

Key finding The historical exploration of psychedelics for easing dying-related anxiety offers insights into current discussions on their use in palliative care.

Abstract

This article examines the historical relationship between psychedelics and palliative care. Historians have contributed to a growing field of studies about how psychedelics have been used in the past, but much of that scholarship focused on interrogating questions of legitimacy or proving that psychedelics had therapeutic potential. Palliative care had not yet developed as medical sub-specialty, more often leaving dying care on the margins of modern, pharmaceutical-based treatments. As psychedelic researchers in the 1950s began exploring different applications for psychoactive substances such as LSD and mescaline, however, dying care came into clearer focus as a potential avenue for psychedelics. Before that application gained momentum in clinical or philosophical discussions, psychedelics were criminalized and some of those early discussions were lost. This article looks back at historical discussions about LSD's potential for easing the anxiety associated with dying, and considers how those early conversations might offer insights into today's more articulated discussions about psychedelics in palliative care.

Tags

Comments

No comments yet.

Log in to comment